Loading…
Capping Prescription Costs Act of 2021
Legislative Progress
Introduced
December 9, 2021
Latest Action
December 10, 2021
Primary Sponsor
Kathy E. ManningDemocratic(NC)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
43pct
1d open
vs 9,698 other HR bills in the 117th — cohort avg 63d
Capping Prescription Costs Act of 20 21 This bill caps the monthly cost-sharing amount permitted for prescription drugs under qualified health plans and group health plans.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2022 · first_quarter · Health Issues
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines H.R. 550: Immunization Infrastructure Modernization Act (IIS harmonization) H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 1400: COVID-19 Health Disparities Action Act of 2021 - Provisions related to COVID-19 vaccines H.R. 1730: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2181: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation H.R. 2565: FDA Modernization Act of 2021 - Provisions related to FDA policy and health research H.R. 2815: BIOSIM Act - Provisions related to biosimilars and prescription drug pricing H.R. 2831: Prompt Approval of Safe Generic Drugs Act- Provisions related to FDA policy and approvals H.R. 2869: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing H.R. 2883: Stop Stalling Access to Affordable Medications - Provisions related to citizen petitions H.R. 3656/S. 3087: Vaccine Access Improvement Act (VICP program changes) H.R. 3761: Promising Pathways Act - Provisions related to FDA policy H.R. 3932: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues H.R. 4127: DISARM Act Provisions related to antimicrobial drug development H.R. 4390: PROTECT 340B Act of 2021 - Provisions related to 340B drug discount program H.R. 4472: BENEFIT Act of 2021 - Provisions related to FDA policy H.R. 4511: FDA Advancing Collection of Transformative Science Act or the FACTS Act H.R. 5030: DIVERSE Trials Act - Provisions related to clinical trial diversity H.R. 5416: Give Kids a Chance Act H.R. 5585: Advanced Research Project Agency-Health Act - Provisions related to health research H.R. 5801: HELP Copays Act - Provisions related to prescription drug pricing and cost-sharing H.R. 6000: Cures 2.0 Act - Provisions related to health research H.R. 6228: Capping Prescription Costs Act of 2021 - Provisions related to prescription drug pricing and cost-sharing H.R. 6584: DEPICT Act - To direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes H.R. 6888: Helping Experts Accelerate Rare Treatments Act of 2022 H.R. 6963: Accelerated Approval Integrity Act of 2022 - Provisions related to accelerated approval H.R. 6972: Give Kids a Chance Act of 2022 - Provisions related to additional authorities and pediatric investigations H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022 - Provisions related to labeling H.R. 6988: Drug Manufacturing Innovation Act of 2022 H.R. 6996: Accelerating Access for Patients Act of 2022 H.R. 7006: Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act H.R. 7008: Pre-Approval Information Exchange Act of 2022 H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 H.R. 7035: Biologics Market Transparency Act of 2022 H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: Ensuring Timely Access to Generics Act of 2021 - Provisions related to citizen petitions S. 670: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. - Provisions related to 340B drug discount program S. 912/H.R. 1978: Protecting Seniors Through Immunization Act S. 920: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation S. 1425: Stop STALLING Act - Provisions related to citizen petitions S. 1427: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing S. 1462: Simplifying the Generic Drug Application Process Act - Provisions related to FDA policy and approvals S. 1463: Modernizing Therapeutic Equivalence Rating Determination Act S. 1644: Promising Pathway Act - Provisions related to FDA policy S. 1645: ADAPT Act - Provisions related to FDA policy S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues S. 2428: False Claims Amendments Act of 2021 - Provisions related to False Claims Act S. 2429: Administrative False Claims Act of 2021 - Provisions related to False Claims Act S. 2706: DIVERSE Trials Act - Provisions related to FDA policy S. 2837: 340B Accountability Act of 2021 - Provisions related to 340B drug discount program S. 2983: ADAPT for COVID Act - Provisions related to FDA accelerated approval pathways S. 3291: STAAR Act - Provisions related to health research and antibiotic resistance S. 3449: Registration of Certain Foreign Establishments Act S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act Cancer Moonshot Initiative 21st Century Cures 2.0 RFI for Advanced Research Projects Agency - Health (ARPA-H) Department of Homeland Security cybersecurity policy issues Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Drug counterfeiting policy issues PDUFA reauthorization BsUFA reauthorization Competition policy issues Orphan Drug Act (ODA) policy issues Health Advanced Research Projects Agency (HARPA) proposal Expanded access policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain and foreign manufacturing policy issues Real world evidence policy issues Clinical trial diversity policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues/Emergency supplemental funding Pandemic preparedness policy issues Defense Production Act (DPA) policy issues Final Rule; Importation of Prescription Drugs Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Nomination of Robert Califf to FDA Commissioner HSA/FSA for Dietary Supplements Dietary Supplement Health and Education Act Reform
Client expense: $1,100,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2022 · first_quarter · Health Issues
H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines H.R. 550: Immunization Infrastructure Modernization Act (IIS harmonization) H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 1400: COVID-19 Health Disparities Action Act of 2021 - Provisions related to COVID-19 vaccines H.R. 1730: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2181: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation H.R. 2565: FDA Modernization Act of 2021 - Provisions related to FDA policy and health research H.R. 2815: BIOSIM Act - Provisions related to biosimilars and prescription drug pricing H.R. 2831: Prompt Approval of Safe Generic Drugs Act- Provisions related to FDA policy and approvals H.R. 2869: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing H.R. 2883: Stop Stalling Access to Affordable Medications - Provisions related to citizen petitions H.R. 3656/S. 3087: Vaccine Access Improvement Act (VICP program changes) H.R. 3761: Promising Pathways Act - Provisions related to FDA policy H.R. 3932: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues H.R. 4127: DISARM Act Provisions related to antimicrobial drug development H.R. 4390: PROTECT 340B Act of 2021 - Provisions related to 340B drug discount program H.R. 4472: BENEFIT Act of 2021 - Provisions related to FDA policy H.R. 4511: FDA Advancing Collection of Transformative Science Act or the FACTS Act H.R. 5030: DIVERSE Trials Act - Provisions related to clinical trial diversity H.R. 5416: Give Kids a Chance Act H.R. 5585: Advanced Research Project Agency-Health Act - Provisions related to health research H.R. 5801: HELP Copays Act - Provisions related to prescription drug pricing and cost-sharing H.R. 6000: Cures 2.0 Act - Provisions related to health research H.R. 6228: Capping Prescription Costs Act of 2021 - Provisions related to prescription drug pricing and cost-sharing H.R. 6584: DEPICT Act - To direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes H.R. 6888: Helping Experts Accelerate Rare Treatments Act of 2022 H.R. 6963: Accelerated Approval Integrity Act of 2022 - Provisions related to accelerated approval H.R. 6972: Give Kids a Chance Act of 2022 - Provisions related to additional authorities and pediatric investigations H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022 - Provisions related to labeling H.R. 6988: Drug Manufacturing Innovation Act of 2022 H.R. 6996: Accelerating Access for Patients Act of 2022 H.R. 7006: Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act H.R. 7008: Pre-Approval Information Exchange Act of 2022 H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 H.R. 7035: Biologics Market Transparency Act of 2022 H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: Ensuring Timely Access to Generics Act of 2021 - Provisions related to citizen petitions S. 670: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. - Provisions related to 340B drug discount program S. 912/H.R. 1978: Protecting Seniors Through Immunization Act S. 920: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation S. 1425: Stop STALLING Act - Provisions related to citizen petitions S. 1427: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing S. 1462: Simplifying the Generic Drug Application Process Act - Provisions related to FDA policy and approvals S. 1463: Modernizing Therapeutic Equivalence Rating Determination Act S. 1644: Promising Pathway Act - Provisions related to FDA policy S. 1645: ADAPT Act - Provisions related to FDA policy S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues S. 2428: False Claims Amendments Act of 2021 - Provisions related to False Claims Act S. 2429: Administrative False Claims Act of 2021 - Provisions related to False Claims Act S. 2706: DIVERSE Trials Act - Provisions related to FDA policy S. 2837: 340B Accountability Act of 2021 - Provisions related to 340B drug discount program S. 2983: ADAPT for COVID Act - Provisions related to FDA accelerated approval pathways S. 3291: STAAR Act - Provisions related to health research and antibiotic resistance S. 3449: Registration of Certain Foreign Establishments Act S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act Cancer Moonshot Initiative 21st Century Cures 2.0 RFI for Advanced Research Projects Agency - Health (ARPA-H) Department of Homeland Security cybersecurity policy issues Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Drug counterfeiting policy issues PDUFA reauthorization BsUFA reauthorization Competition policy issues Orphan Drug Act (ODA) policy issues Health Advanced Research Projects Agency (HARPA) proposal Expanded access policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain and foreign manufacturing policy issues Real world evidence policy issues Clinical trial diversity policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues/Emergency supplemental funding Pandemic preparedness policy issues Defense Production Act (DPA) policy issues Final Rule; Importation of Prescription Drugs Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Nomination of Robert Califf to FDA Commissioner HSA/FSA for Dietary Supplements Dietary Supplement Health and Education Act Reform
Client expense: $830,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $100,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $40,000
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
2022 · first_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
2022 · first_quarter · Health Issues
H.R. 5: Equality Act H.R. 349: Coronavirus Vaccine and Therapeutic Development Act of 2021 - Provisions related to manufacturing of COVID-19 treatments and vaccines H.R. 724: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021 - Provisions related to FDA drug approval process H.R. 832: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation H.R. 1400: COVID-19 Health Disparities Action Act of 2021 - Provisions related to COVID-19 vaccines H.R. 1730: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research H.R. 1873: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products H.R. 2181: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation H.R. 2565: FDA Modernization Act of 2021 - Provisions related to FDA policy and health research H.R. 2815: BIOSIM Act - Provisions related to biosimilars and prescription drug pricing H.R. 2831: Prompt Approval of Safe Generic Drugs Act- Provisions related to FDA policy and approvals H.R. 2843: STOP GAMES Act of 2021 - Provisions related to citizen petitions H.R. 2869: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing H.R. 2883: Stop Stalling Access to Affordable Medications - Provisions related to citizen petitions H.R. 3085: ENACT Act of 2021- Sets out activities and requirements to increase the participation of underrepresented populations in research and clinical trials for Alzheimers disease and related dementias H.R. 3761: Promising Pathways Act - Provisions related to FDA policy H.R. 3932: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues H.R. 4390: PROTECT 340B Act of 2021 - Provisions related to 340B drug discount program H.R. 4472: BENEFIT Act of 2021 - Provisions related to FDA policy H.R. 4511: FDA Advancing Collection of Transformative Science Act or the FACTS Act H.R. 5030: DIVERSE Trials Act - Provisions related to clinical trial diversity H.R. 5416: Give Kids a Chance Act H.R. 5585: Advanced Research Project Agency-Health Act - Provisions related to health research H.R. 5801: HELP Copays Act - Provisions related to prescription drug pricing and cost-sharing H.R. 6000: Cures 2.0 Act - Provisions related to health research H.R. 6228: Capping Prescription Costs Act of 2021 - Provisions related to prescription drug pricing and cost-sharing H.R. 6584: DEPICT Act - To direct the Commissioner of Food and Drugs to amend certain regulations to increase clinical trial diversity, and for other purposes H.R. 6888: Helping Experts Accelerate Rare Treatments Act of 2022 H.R. 6963: Accelerated Approval Integrity Act of 2022 - Provisions related to accelerated approval H.R. 6972: Give Kids a Chance Act of 2022 - Provisions related to additional authorities and pediatric investigations H.R. 6973: Enhanced Access to Affordable Medicines Act of 2022 - Provisions related to labeling H.R. 6988: Drug Manufacturing Innovation Act of 2022 H.R. 6996: Accelerating Access for Patients Act of 2022 H.R. 7006: Improving the Nations Safe Pharmaceuticals and Excipients by Creating Tools for Inspecting and Overseeing Needed Supplies Act or the INSPECTIONS Act H.R. 7008: Pre-Approval Information Exchange Act of 2022 H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022 H.R. 7035: Biologics Market Transparency Act of 2022 H.R. 7047: Lowering Costs by Improving Biosimilar Uptake Act S. 154: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2021- Provisions related to FDA drug approval process S. 164: Advancing Education on Biosimilars Act of 2021 - Provisions related to biologics and biosimilar products S. 259: Safe and Affordable Drugs from Canada Act of 2021 - Provisions related to prescription drug importation S. 562: Ensuring Timely Access to Generics Act of 2021 - Provisions related to citizen petitions S. 670: Speeding Therapy Access Today Act of 2021 - Provisions related to FDA policy and health research S. 773: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes. - Provisions related to 340B drug discount program S. 920: Affordable and Safe Prescription Drug Importation Act - Provisions related to prescription drug importation S. 1425: Stop STALLING Act - Provisions related to citizen petitions S. 1427: Increasing Access to Biosimilars Act of 2021 - Provisions related to biosimilars and prescription drug pricing S. 1462: Simplifying the Generic Drug Application Process Act - Provisions related to FDA policy and approvals S. 1463: Modernizing Therapeutic Equivalence Rating Determination Act S. 1548: ENACT Act of 2021 - To amend the Public Health Service Act to improve the diversity of participants in research on Alzheimers disease, and for other purposes S. 1644: Promising Pathway Act - Provisions related to FDA policy S. 1645: ADAPT Act - Provisions related to FDA policy S. 2076: PASTEUR Act of 2021 - Provisions related to antimicrobial resistance policy issues S. 2428: False Claims Amendments Act of 2021 - Provisions related to False Claims Act S. 2429: Administrative False Claims Act of 2021 - Provisions related to False Claims Act S. 2706: DIVERSE Trials Act - Provisions related to FDA policy S. 2837: 340B Accountability Act of 2021 - Provisions related to 340B drug discount program S. 2983: ADAPT for COVID Act - Provisions related to FDA accelerated approval pathways S. 3291: STAAR Act - Provisions related to health research and antibiotic resistance S. 3449: Registration of Certain Foreign Establishments Act S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics Act or PREVENT Pandemics Act Cancer Moonshot Initiative 21st Century Cures 2.0 RFI for Advanced Research Projects Agency - Health (ARPA-H) Department of Homeland Security cybersecurity policy issues Drug cost and pricing policy issues Principles for drug pricing reform Drug importation policy issues Drug counterfeiting policy issues PDUFA reauthorization BsUFA reauthorization Competition policy issues Orphan Drug Act (ODA) policy issues Health Advanced Research Projects Agency (HARPA) proposal Expanded access policy issues Antimicrobial resistance (AMR) policy issues High deductible health plans/HSA policy issues Supply chain and foreign manufacturing policy issues Real world evidence policy issues Clinical trial diversity policy issues FDA modernization policy issues 340B drug discount program policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues Regulatory efficiencies policy issues COVID-19 policy issues Pandemic preparedness policy issues Defense Production Act (DPA) policy issues Nomination of Robert Califf to FDA Commissioner Final Rule; Importation of Prescription Drugs Buy America and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients
2021 · fourth_quarter · Pharmacy
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act - Rep. Pallone, Frank, Jr. [D-NJ-6] - drug pricing H.R. 153 - Protecting Consumer Access to Generic Drugs Act of 2021 - Rep. Rush, Bobby L. [D-IL-1] - generic drugs H.R. 1829 - Pharmacy Benefit Manager Accountability Study Act of 2021 - Rep. Harshbarger, Diana [R-TN-1] - PBMs H.R. 1873 - Advancing Education on Biosimilars Act of 2021 - Rep. Bucshon, Larry [R-IN-8] - drug education H.R. 2071 - Medicare Prescription Drug Price Negotiation Act of 2021 - Rep. Welch, Peter [D-VT-At Large] - Part D price negotiation H.R. 2139 - Medicare Drug Price Negotiation Act - Rep. Doggett, Lloyd [D-TX-35] - Part D price negotiation H.R. 2148 - Prescription Drug Price Relief Act of 2021 - Rep. Khanna, Ro [D-CA-17] - excessive drug pricing H.R. 2608 - Ensuring Seniors Access to Local Pharmacies Act of 2021 - Rep. Welch, Peter [D-VT-At Large] - rural health H.R. 2829 - End Price Gouging for Medications Act - Rep. Welch, Peter [D-VT-At Large] - reference prices H.R. 2846 - Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 - Rep. McKinley, David B. [R-WV-1] - biosimilar drugs H.R. 2855 - Star Rating for Biosimilars Act - Rep. Tonko, Paul [D-NY-20] - biosimilar drugs H.R. 2891 - Preserve Access to Affordable Generics and Biosimilars Act - Rep. Nadler, Jerrold [D-NY-10] - biosimilar drugs H.R. 3831 - Seniors Securing Access to Vital and Essential Prescription Drugs Act - Rep. Lee, Susie [D-NV-3] - Part D H.R. 4121 - PRO Seniors Act - Rep. Arrington, Jodey C. [R-TX-19] - drug rebates H.R. 4417 - Capping Drug Costs for Seniors Act of 2021 - Rep. Horsford, Steven [D-NV-4] - reduces out of pocket spending H.R. 4418 - SPIKE Act - Rep. Horsford, Steven [D-NV-4] - Medicare drug price threshold H.R. 5623 - The Insulin Cost Reduction Act - Rep. Grothman, Glenn [R-WI-6] - insulin prices under part D H.R. 6000 - Cures 2.0 Act - Rep. DeGette, Diana [D-CO-1] - drug development H.R. 6228 - To limit cost sharing for prescription drugs - Rep. Manning, Kathy E. [D-NC-6] - cost sharing S. 298 - Pharmacy Benefit Manager Accountability Study Act of 2021 - Sen. Blackburn, Marsha [R-TN] - PBMs S. 833 - Empowering Medicare Seniors to Negotiate Drug Prices Act of 2021 - Sen. Klobuchar, Amy [D-MN] - Part D price negotiation S. 898 - Fair Accountability and Innovative Research Drug Pricing Act of 2021 - Sen. Baldwin, Tammy [D-WI] - reporting price increases S. 908 - Medicare Drug Price Negotiation Act - Sen. Sanders, Bernard [I-VT] - Part D price negotiation S. 1123 - PING Act - Sen. Blackburn, Marsha [R-TN] - Part D non-interference S. 1323 - End Price Gouging for Medications Act - Sen. Merkley, Jeff [D-OR] - reference prices S. 1428 - Preserve Access to Affordable Generics and Biosimilars Act - Sen. Klobuchar, Amy [D-MN] - biosimilar drugs S. 2257 - Expanding Access to Affordable Prescription Drugs and Medical Devices Act - Sen. Rosen, Jacky [D-NV] - drug shortages and costs S. 2304 - DTC Act of 2021- Sen. Durbin, Richard J. [D-IL] - drug pricing S. 2327 - Seniors Prescription Drug Relief Act - Sen. Cassidy, Bill [R-LA] - Medicare part D modernization redesign and reduces out of pocket spending S. 2815 - Seniors Saving on Insulin Act - Sen. Kennedy, John [R-LA] - Part D Senior Savings model S. 3339 - A bill to limit cost sharing for prescription drugs - Sen. Warnock, Raphael G. [D-GA] - cost sharing Regulatory Issues: Issues relating to long term safety and effectiveness of medical devices and drugs, including registries; issues relating to post-market surveillance of drugs and medical devices; issues relating to price of drugs and biologics and proposals to limit high prices; issues related to prescription drug coupons and discount programs; issues relating to vaccines; issues related to health equity; issues related to vaccination; potential Medicare NCD relating to monoclonal antibodies for treatment of Alzheimers disease; Executive Orders relating to international pricing, Part D rebates, insulin costs, and importation; issues related to drug patents and market exclusivity; issues related to pharmacy benefit managers; issues related to biosimilars; issues related to approval of drugs and biologics; issues relating to opioids; issues relating to COVID-19, including vaccines and therapeutics; issues related to health care price transparency; issues relating to prescription drug rebates; direct-to-consumer advertising for prescription drugs; issues related to proposed changes to removal of safe harbor protection for rebates (proposed rule); issues relating to access for investigational drugs; and other issues relating to health care reform implementation.
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: $40,000 · Firm income: Not reported
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $10,000
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $100,000
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $40,000
2021 · fourth_quarter · Health Issues
Medicare Area Wage Index - New Brunswick-Lakewood CBSA; Radiation Oncology Model; Surprise Billing - Qualified Payment Amount; Site-neutral payment/BBA 2015 Sec. 603; Build Back Better Act (H.R. 5376); Protecting Medicare and American Farmers from Sequester Cuts Act (S. 610); Protecting the American Taxpayer and Medicare Act (S. 3344); Supporting Health Care Providers During the COVID-19 Pandemic Act (H.R. 6143); Supporting Medicare Providers Act of 2021 (S. 3314); Infrastructure Investment and Jobs Act (H.R. 3684); Resident Physician Shortage Reduction Act of 2021 (S.834); Accelerating Access to Critical Therapies for ALS Act (H.R. 3537/S. 1813); Comprehensive Addiction Resources Emergency Act of 2021 (H.R. 6311/S. 3418); Expanding Medical Education Act (H.R. 801/S. 3422); Opioid Treatment Access Act of 2022 (H.R. 6279); Dr. Lorna Breen Health Care Provider Protection Act (H.R. 1667); Capping Prescription Costs Act of 2021 (H.R. 6228/S. 3339); No COVID-19 Vaccination Mandate Act of 2021 (H.R. 6170); Cures 2.0 Act (H.R. 6000); Respecting Our Frontline Workers Act (S. 3225); Provider Relief Fund Improvement Act (H.R. 5963); Inpatient Opioid Safety Act of 2021 (H.R. 5932); LOCAL HEALTH Act (H.R. 5898); Keeping Our COVID-19 Heroes Employed Act (H.R. 5860); Expanded Telehealth Access Act (H.R. 2168/S. 3193); Healthy Competition for Better Care Act (S. 3139); Hospital Revitalization Act of 2021 (S. 3105); Choose Home Care Act of 2021 (H.R. 5514/S. 2562); Good Samaritan Health Professionals Act of 2021 (H.R. 5239/S. 2941); 340B Accountability Act of 2021 (S. 2837).
Client expense: Not reported · Firm income: $20,000
| Democratic |
| FL |
| Lucy McBath | Democratic | GA |
| Marie Newman | Democratic | IL |
| Nikema Williams | Democratic | GA |
| Peter Welch | Democratic | VT |
| Steve Cohen | Democratic | TN |
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: $8,070,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS)
Client expense: $2,630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, SENATE